CY1116045T1 - COMPOSITIONS AND METHODS FOR EYE DISORDER TREATMENT - Google Patents

COMPOSITIONS AND METHODS FOR EYE DISORDER TREATMENT

Info

Publication number
CY1116045T1
CY1116045T1 CY20151100187T CY151100187T CY1116045T1 CY 1116045 T1 CY1116045 T1 CY 1116045T1 CY 20151100187 T CY20151100187 T CY 20151100187T CY 151100187 T CY151100187 T CY 151100187T CY 1116045 T1 CY1116045 T1 CY 1116045T1
Authority
CY
Cyprus
Prior art keywords
lfa
methods
compositions
mediated
eye disorder
Prior art date
Application number
CY20151100187T
Other languages
Greek (el)
Inventor
Thomas Gadek
John Burnier
Original Assignee
Sarcode Bioscience Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06770607.7A external-priority patent/EP1881823B1/en
Application filed by Sarcode Bioscience Inc. filed Critical Sarcode Bioscience Inc.
Publication of CY1116045T1 publication Critical patent/CY1116045T1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ενώσεις και μεθόδους για την θεραπεία ασθενειών που προκαλούνται με την μεσολάβηση του LFA-1. Ειδικότερα, στην παρούσα περιγράφονται ανταγωνιστικά LFA-1 και αυτά τα ανταγωνιστικά χρησιμοποιούνται στην θεραπεία ασθενειών που προκαλούνται με την μεσολάβηση του LFA-1. Μία όψη της εφεύρεσης παρέχει την διάγνωση μιας ασθένειας που προκαλείται με την μεσολάβηση του LFA-1 και την χορήγηση ενός ανταγωνιστικού LFA-1, μετά την διάγνωση ότι ο ασθενής έχει μία ασθένεια που προκαλείται με την μεσολάβηση του LFA-1. Σε μερικές υλοποιήσεις, οι ασθένειες που προκαλούνται με την μεσολάβηση του LFA-1 είναι διαταραχές ξηρών ματιών. Επίσης στην παρούσα παρέχονται μέθοδοι για την αναγνώριση ενώσεων που είναι ανταγωνιστικά του LFA-1.The present invention provides compounds and methods for the treatment of diseases mediated by LFA-1. In particular, hereinafter described are LFA-1 antagonists and these antagonists are used in the treatment of diseases mediated by LFA-1. One aspect of the invention provides the diagnosis of a disease mediated by LFA-1 and the administration of an antagonist LFA-1, after the diagnosis that the patient has a disease mediated by LFA-1. In some embodiments, LFA-1-mediated diseases are dry eye disorders. Also provided herein are methods for identifying compounds that are antagonistic to LFA-1.

CY20151100187T 2005-05-17 2015-02-20 COMPOSITIONS AND METHODS FOR EYE DISORDER TREATMENT CY1116045T1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US68172205A 2005-05-17 2005-05-17
US68177205A 2005-05-17 2005-05-17
US68168405A 2005-05-17 2005-05-17
US68172305A 2005-05-17 2005-05-17
EP06770607.7A EP1881823B1 (en) 2005-05-17 2006-05-17 Compositions and methods for treatment of eye disorders

Publications (1)

Publication Number Publication Date
CY1116045T1 true CY1116045T1 (en) 2017-01-25

Family

ID=58457256

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100187T CY1116045T1 (en) 2005-05-17 2015-02-20 COMPOSITIONS AND METHODS FOR EYE DISORDER TREATMENT

Country Status (1)

Country Link
CY (1) CY1116045T1 (en)

Similar Documents

Publication Publication Date Title
CY1118660T1 (en) COMPOSITIONS AND METHODS FOR EYE DISORDER TREATMENT
CY1123050T1 (en) INDOLIDONE DRUGS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
CY1124446T1 (en) RUXOLITINIB EXTENDED RELEASE DOSAGE FORMS
CY1121593T1 (en) TETRAHYDROCANNAVINOL PRODUCTS, COMPOSITIONS INCLUDING TETRAHYDROCANNAVINOL PRODUCTS AND METHODS FOR USING THE SAME
CY1118695T1 (en) SUSPENSIONS OF STONES
CO6290757A2 (en) N- (2 (HETARL) ARI) ARILSULPHONAMIDS AND N- (2- (HETARIL) HETARIL) ARILSULFONAMIDS
CY1117312T1 (en) Therapeutic treatment of cochlecopenia
CY1117726T1 (en) POSITIVE ALLOYSTERIC RETURNS M1 KINOLINAMIDE RECEPTORS
CY1115316T1 (en) Peptides for Beta-Amyloidosis Therapeutic Treatment
CY1117817T1 (en) Substituted acylanilides and methods of their use
CY1117317T1 (en) JANUS KINASE DISPOSALS FOR DRY COTTAGE AND OTHER DISEASE DISEASES
CY1118819T1 (en) HETROCYCLE UNIONS IP HOLDING AGENTS
CY1116333T1 (en) FUZZOURANI PRODUCERS AS FXR REGULATORY PARTS
CY1118452T1 (en) UNITS AND COMPOSITIONS AS PROTEIN MODEL SUSPENSIONS
PA8595901A1 (en) "N-ARILHETEROCICLOS REPLACED, PROCEDURES FOR THEIR PREPARATION, AND THEIR EMPLOYMENT AS MEDICATIONS
CY1111757T1 (en) XANTHINI PRODUCTS AS ELECTRIC SUSPENSIONS HM74A
CY1117584T1 (en) 1-Benzyl-3-hydroxymethyldazole derivative and their use in the therapeutic treatment of MCP-1-expressing MC3-C3
CL2008002506A1 (en) Compounds derived from substituted benzimidazole, preparation process, pharmaceutical composition, useful in the treatment of diseases modulated with antagonists of the fxr receptor, in particular for the treatment of increased levels of lipids and / or cholesterol, atherosclerotic disease, diabetes, cancer, parkinson's , Alzheimer's.
CY1113798T1 (en) Substituted Diazepane Compounds as Orexin Receptor Competitors
UY30477A1 (en) DERIVATIVES OF [4,5 '] BIPIRIMIDINIL-6,4´-DIAMINE AS PROTEIN KINASE INHIBITORS
CY1111977T1 (en) PEPERIDIN-4-YL-PYRIDAZIN-3-YLAMINE DERIVATIVES AS HIGHLY DISTRIBUTED DOPAMIN COMPONENTS 2
CL2009000349A1 (en) Compounds derived from 4,5-dihydro-oxazol-2-ylamine; preparation procedure; pharmaceutical composition; and its use for the treatment of Alzheimer's disease.
EA201070148A1 (en) CONNECTIONS AND METHODS FOR MODELING THE PHARNECIDE RECEPTOR X (FXR)
EA201100691A1 (en) ANTAGONISTS OF LYSOPHPATIDIC ACID RECEPTORS
EA201791669A2 (en) NEW THERAPEUTIC APPROACHES IN THE TREATMENT OF SMT AND RELATED DISORDERS